Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05088226

Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Peripheral Blood Stem Cell Transplantation Clinical Trial

Official title:
Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen for Patients With Acute B Cell Lymphoblast Leukemia Underwenting Haploidenticl Peripheral Blood Stem Cell Transplantation

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.

Clinical Trial Description

Haploidenticl Peripheral blood Stem Cell Transplantation should be offered to eligible patients with Acute B cell Lymphoblast leukemia whenever feasible. To further improve the outcome of transplantation patients with Acute B cell Lymphoblast leukemia, we developed a modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide. In this study, we tested the efficacy and feasibility of the modified Bu/Cy conditioning regimen intensified by Ruxolitinib and Chidamide in patients with Acute B cell Lymphoblast leukemia undergoing allogeneic peripheral blood stem cell transplantation. ;

Study Design

Related Conditions & MeSH terms

  • Peripheral Blood Stem Cell Transplantation
Clinical Trial Details
NCT number NCT05088226
Study type Interventional
Source Chinese PLA General Hospital
Contact Daihong Liu
Phone 86-13681171597
Email daihongrm@163.com
Status Recruiting
Phase Phase 2
Start date December 1, 2021
Completion date June 1, 2023
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04582604 - Ruxolitinib and Decitabine for High Risk Hematological Malignancies Phase 1/Phase 2
Recruiting NCT05436418 - The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation Phase 1/Phase 2
Recruiting NCT05075681 - Ruxolitinib and Chidamide for Acute T Cell Lymphoblast Leukemia/ Lymphoblastic Lymphoma Phase 1/Phase 2
Completed NCT03993639 - KRN125 for Mobilization of Hematopoietic Stem Cells Phase 2
Completed NCT02398708 - Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
Completed NCT00575809 - Incidence and Factors Associated With the Development and Severity of Oral Mucositis
Completed NCT00670423 - A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation Phase 1
Terminated NCT02326675 - Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant N/A
Recruiting NCT05153226 - GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG Phase 3
Recruiting NCT02848105 - Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD Phase 2
Not yet recruiting NCT03771222 - Prophylactic Donor Lymphocyte Infusion After Allo-PBSCT for Patients With Very High-risk Hematologic Malignancies Phase 2
Completed NCT02512679 - Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells Phase 2
Recruiting NCT05961410 - Eltrombopag for Peripheral Blood Stem Cell Harvest Phase 2